{"id":12028,"date":"2025-10-10T15:09:42","date_gmt":"2025-10-10T08:09:42","guid":{"rendered":"https:\/\/nhathuocngocanh.com\/bp\/?p=12028"},"modified":"2025-10-10T15:10:31","modified_gmt":"2025-10-10T08:10:31","slug":"dexamfetamine-sulfate","status":"publish","type":"post","link":"https:\/\/nhathuocngocanh.com\/bp\/dexamfetamine-sulfate\/","title":{"rendered":"Dexamfetamine Sulfate"},"content":{"rendered":"

(Ph. Eur. monograph 2752)<\/em><\/p>\n

C18<\/sub>H28<\/sub>N2<\/sub>O4<\/sub>S 368.5 51-63-8<\/p>\n

Action and use<\/strong><\/p>\n

Amfetamine.<\/p>\n

Preparation<\/strong><\/p>\n

Dexamfetamine Tablets<\/p>\n

DEFINITION<\/h2>\n

Bis[(2S)-1-phenylpropan-2-amine] sulfate.<\/p>\n

Content<\/h3>\n

99.0 per cent to 101.0 per cent (dried substance).<\/p>\n

CHARACTERS<\/h2>\n

Appearance<\/h3>\n

White or almost white powder.<\/p>\n

Solubility<\/h3>\n

Freely soluble in water, very slightly soluble in ethanol (96 per cent), practically insoluble in methylene chloride.<\/p>\n

IDENTIFICATION<\/h2>\n

First identification: A, B, D.<\/p>\n

Second identification: C, D.<\/p>\n

Dexamfetamine Sulfate<\/h3>\n

A. Enantiomeric purity (see Tests).<\/p>\n

B. Infrared absorption spectrophotometry (2.2.24).<\/p>\n

Comparison: dexamfetamine sulfate CRS.<\/p>\n

C. To 50 mL of solution S add 5 mL of strong sodium hydroxide solution R and 0.5 mL of benzoyl chloride R and shake.<\/p>\n

Continue to add benzoyl chloride R in portions of 0.5 mL, shaking after each addition, until no further precipitate is formed.<\/p>\n

Filter, wash the precipitate with water R, recrystallise twice from a mixture of equal volumes of ethanol (96 per cent) R and water R, then dry at 100-105 \u00b0C. The crystals melt (2.2.14) at 155 \u00b0C to 160 \u00b0C.<\/p>\n

D. Solution S (see Tests) gives reaction (a) of sulfates (2.3.1).<\/p>\n

TESTS<\/h2>\n

Solution S<\/h3>\n

Dissolve 2.0 g in carbon dioxide-free water R and dilute to 100 mL with the same solvent.<\/p>\n

Appearance of solution<\/p>\n

Solution S is clear (2.2.1) and colourless (2.2.2, Method II).<\/p>\n

Acidity or alkalinity<\/h3>\n

To 25 mL of solution S add 0.1 mL of methyl red solution R. Not more than 0.1 mL of 0.01 M hydrochloric acid or 0.01 M sodium hydroxide is required to change the colour of the indicator.<\/p>\n

Enantiomeric purity<\/h3>\n

Liquid chromatography (2.2.29).<\/p>\n

Test solution Dissolve 25.0 mg of the substance to be examined in methanol R and dilute to 25.0 mL with the same solvent.<\/p>\n

Reference solution (a): Dilute 1.0 mL of the test solution to 20.0 mL with methanol R.<\/p>\n

Reference solution (b): Dissolve 5 mg of amfetamine sulfate CRS (containing impurity E and dexamfetamine) in 5 mL of methanol R.<\/p>\n

Column:<\/p>\n

\u2014 size: l = 0.25 m, \u00d8 = 4.6 mm;<\/p>\n

\u2014 stationary phase: vancomycin-bonded silica gel for chiral separation R (5 \u03bcm);<\/p>\n

\u2014 temperature: 25 \u00b0C.<\/p>\n

Mobile phase: concentrated ammonia R1, glacial acetic acid R, methanol R2 (0.1:1:998.9 V\/V\/V).<\/p>\n

Flow rate: 1.0 mL\/min.<\/p>\n

Detection: Spectrophotometer at 210 nm.<\/p>\n

Injection: 5 \u03bcL.<\/p>\n

Run time: 1.5 times the retention time of dexamfetamine.<\/p>\n

Identification of peaks: Use the chromatogram supplied with amfetamine sulfate CRS and the chromatogram obtained with reference solution (b) to identify the peaks due to dexamfetamine and impurity E.<\/p>\n

Relative retention: With reference to dexamfetamine (retention time = about 10 min): impurity E = about 1.1.<\/p>\n

System suitability: Reference solution (b):<\/p>\n

\u2014 resolution: minimum 2.5 between the peaks due to dexamfetamine and impurity E.<\/p>\n

Calculation of percentage content:<\/p>\n

\u2014 for impurity E, use the concentration of dexamfetamine sulfate in reference solution (a).<\/p>\n

Limit:<\/p>\n

\u2014 impurity E: maximum 5.0 per cent.<\/p>\n

Related substances<\/h3>\n

Liquid chromatography (2.2.29). Prepare the solutions immediately before use.<\/p>\n

Solvent mixture: Mix 5 mL of trifluoroacetic acid R and 900 mL of water for chromatography R, adjust to pH 2.2 with concentrated ammonia R and dilute to 1000 mL with acetonitrile R.<\/p>\n

Test solution: Dissolve 20.0 mg of the substance to be examined in the solvent mixture and dilute to 10.0 mL with the solvent mixture.<\/p>\n

Reference solution (a): Dilute 1.0 mL of the test solution to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.<\/p>\n

Reference solution (b): Dissolve 5 mg of 1-phenylpropan-2-ol R (impurity A) and 5 mg of benzaldehyde R (impurity D) in the solvent mixture and dilute to 10 mL with the solvent mixture. Dilute 1 mL of the solution to 100 mL with the solvent mixture.<\/p>\n

Column:<\/p>\n

\u2014 size: l = 0.15 m, \u00d8 = 4.6 mm;<\/p>\n

\u2014 stationary phase: base-deactivated end-capped octadecylsilyl silica gel for chromatography R (5 \u03bcm);<\/p>\n

\u2014 temperature: 40 \u00b0C.<\/p>\n

Mobile phase:<\/p>\n

\u2014 mobile phase A: solvent mixture;<\/p>\n

\u2014 mobile phase B: acetonitrile R;<\/p>\n\n\n\n\n\n\n\n
Time
\n(min)<\/td>\n		Mobile phase A
\n(per cent V\/V)<\/td>\n		Mobile phase B
\n(per cent V\/V)<\/td>\n<\/tr>\n
0 – 1<\/td>\n100<\/td>\n0<\/td>\n<\/tr>\n
1 – 16<\/td>\n100 \u2192 65<\/td>\n0 \u2192 35<\/td>\n<\/tr>\n
16 – 21<\/td>\n65 \u2192 0<\/td>\n35 \u2192 100<\/td>\n<\/tr>\n
21 – 23<\/td>\n0<\/td>\n100<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Flow rate: 1.5 mL\/min.<\/p>\n

Detection: Spectrophotometer at 257 nm.<\/p>\n

Injection: 20 \u03bcL.<\/p>\n

Identification of impurities: Use the chromatogram obtained with reference solution (b) to identify the peaks due to impurities A and D.<\/p>\n

Relative retention: With reference to dexamfetamine (retention time = about 8 min): impurity D = about 1.6; impurity A = about 1.7.<\/p>\n

System suitability: Reference solution (b):<\/p>\n

\u2014 resolution: minimum 4.0 between the peaks due to impurities D and A.<\/p>\n

Calculation of percentage contents:<\/p>\n

\u2014 for each impurity, use the concentration of dexamfetamine sulfate in reference solution (a).<\/p>\n

Limits:<\/p>\n

\u2014 unspecified impurities: for each impurity, maximum 0.10 per cent;<\/p>\n

\u2014 total: maximum 0.5 per cent;<\/p>\n

\u2014 reporting threshold: 0.05 per cent.<\/p>\n

Loss on drying (2.2.32)<\/h3>\n

Maximum 1.0 per cent, determined on 1.000 g by drying in an oven at 105 \u00b0C.<\/p>\n

Sulfated ash (2.4.14)<\/h3>\n

Maximum 0.1 per cent, determined on 1.0 g.<\/p>\n

ASSAY<\/h2>\n

Dissolve 0.300 g in 30 mL of anhydrous acetic acid R. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.2.20).<\/p>\n

1 mL of 0.1 M perchloric acid is equivalent to 36.85 mg of C18<\/sub>H28<\/sub>N2<\/sub>O4<\/sub>S.<\/p>\n

STORAGE<\/h2>\n

Protected from light.<\/p>\n

IMPURITIES<\/h2>\n

Specified impurities E.<\/p>\n

Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other\/unspecified impurities and\/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use) A, B, C, D.<\/p>\n

\"Dexamfetamine<\/p>\n

A. (2RS)-1-phenylpropan-2-ol,<\/p>\n

\"Dexamfetamine<\/p>\n

B. 1-phenylpropan-2-one,<\/p>\n

\"Dexamfetamine<\/p>\n

C. (2S)-2-amino-1-phenylpropan-1-one (cathinone),<\/p>\n

\"Dexamfetamine<\/p>\n

D. benzaldehyde,<\/p>\n

\"Dexamfetamine<\/p>\n

E. (2R)-1-phenylpropan-2-amine (levamfetamine).<\/p>\n","protected":false},"excerpt":{"rendered":"

(Ph. Eur. monograph 2752) C18H28N2O4S 368.5 51-63-8 Action and use Amfetamine. Preparation Dexamfetamine Tablets DEFINITION Bis[(2S)-1-phenylpropan-2-amine] sulfate. Content 99.0 per cent to 101.0 per cent (dried substance). CHARACTERS Appearance White or almost white powder. Solubility Freely soluble in water, very slightly soluble in ethanol (96 per cent), practically insoluble in methylene chloride. IDENTIFICATION First identification:…<\/p>\n","protected":false},"author":4,"featured_media":12036,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-12028","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/12028","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=12028"}],"version-history":[{"count":3,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/12028\/revisions"}],"predecessor-version":[{"id":12045,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/12028\/revisions\/12045"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/12036"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=12028"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=12028"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=12028"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}